Scholarlink

<p>Transdermal drug delivery (TDD) bypasses first-pass metabolism and improves patient compliance. However, conventional hydrogels are static and cannot adapt to dynamic physiological conditions. Stimuli-responsive photonic hydrogels overcome these limitations by integrating photonic triggers (e.g., photoisomerization, photothermal conversion) with biochemical sensors (e.g., glucose, reactive oxygen species (ROS), enzymes). These systems employ Boolean logic operations to achieve conditional, multi-input gated release. Proof-of-concept studies demonstrate a three-to-five-fold increase in skin penetration, &gt; 70% tumor volume reduction with lower drug doses, and accelerated wound closure compared to passive hydrogels. Embedding these platforms into microneedles and wearable electronics enables real-time, feedback-controlled dosing, while artificial intelligence (AI) offers predictive, closed-loop optimization. Despite their promise, clinical translation requires overcoming challenges in biocompatibility, manufacturing scalability, and regulatory classification. A roadmap emphasizing standardized safety testing, modular fabrication, and AI-guided prototyping is essential. Photonic hydrogels thus mark a paradigm shift, advancing transdermal systems from static depots to adaptive, autonomous therapeutics for personalized medicine.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Programmable multi-stimuli photonic hydrogels for intelligent and adaptive transdermal drug delivery

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月30日

查看全文
  • Mahmoud Mohamed Omar,
  • Ramadan A. M. Hemeida,
  • Ehab E. Sharata,
  • Obaid Alfazl,
  • Randa Mohammed Zaki,
  • Amany A. Abdel-Rheem,
  • Omiya Ali Hasan

摘要

Transdermal drug delivery (TDD) bypasses first-pass metabolism and improves patient compliance. However, conventional hydrogels are static and cannot adapt to dynamic physiological conditions. Stimuli-responsive photonic hydrogels overcome these limitations by integrating photonic triggers (e.g., photoisomerization, photothermal conversion) with biochemical sensors (e.g., glucose, reactive oxygen species (ROS), enzymes). These systems employ Boolean logic operations to achieve conditional, multi-input gated release. Proof-of-concept studies demonstrate a three-to-five-fold increase in skin penetration, > 70% tumor volume reduction with lower drug doses, and accelerated wound closure compared to passive hydrogels. Embedding these platforms into microneedles and wearable electronics enables real-time, feedback-controlled dosing, while artificial intelligence (AI) offers predictive, closed-loop optimization. Despite their promise, clinical translation requires overcoming challenges in biocompatibility, manufacturing scalability, and regulatory classification. A roadmap emphasizing standardized safety testing, modular fabrication, and AI-guided prototyping is essential. Photonic hydrogels thus mark a paradigm shift, advancing transdermal systems from static depots to adaptive, autonomous therapeutics for personalized medicine.

Graphical Abstract